MRI Study of Antidepressants in the Treatment of Refractory Functional Dyspepsia

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03973567
Collaborator
(none)
90
1
3
41
2.2

Study Details

Study Description

Brief Summary

In this study, diffusion tensor imaging(DTI)technique was used to evaluate the brain microstructures and connective white matter microstructures in patients with refractory FD, resting fMRI was used to evaluate the functional connectivity between hemispheres, and neuroimaging changes after antidepressant intervention were observed to explore the activation patterns of resting brain homeostasis-receptive network areas in patients with refractory FD. We aimed to explore microstructure of white matter and gray matter and functional connectivity between hemispheres to explain the therapeutic mechanism of antidepressants.

Condition or Disease Intervention/Treatment Phase
  • Drug: selective serotonin reuptake inhibitor (SSRI) or serotonin noradrenaline reuptake inhibitor (SNRI) antidepressants
  • Other: conventional therapy
N/A

Detailed Description

In this study, functional magnetic resonance imaging (fMRI) was used to investigate the abnormal activation patterns of brain regions in patients with refractory FD in resting state, and to observe the changes of brain functions after antidepressant treatment, in order to find scientific evidence for exploring the etiology, neuropathological mechanism and the mechanism of antidepressant treatment of refractory FD.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
90 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Magnetic Resonance Imaging Study of Antidepressants in the Treatment of Refractory Functional Dyspepsia
Actual Study Start Date :
Jan 1, 2017
Anticipated Primary Completion Date :
Dec 31, 2019
Anticipated Study Completion Date :
Jun 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: refractory FD patients using antidepressants

Sixty FD patients who met the criteria were selected as the experimental group after more than two kinds of treatment, including acid-making, proton pump inhibitors (PPI), motivation and anti-Helicobacter pylori(HP) treatment, including 30 in the conventional treatment group and 30 in the combined antidepressant treatment group.

Drug: selective serotonin reuptake inhibitor (SSRI) or serotonin noradrenaline reuptake inhibitor (SNRI) antidepressants
On the basis of routine treatment for 8-12 weeks, according to the characteristics of symptoms, a combination of SSRI or SNRI antidepressant drugs was given for 12 weeks.

Placebo Comparator: refractory FD patienTS using conventional treatment

Sixty FD patients who met the criteria were selected as the experimental group after more than two kinds of treatment, including acid-making, PPI, motivation and anti-HP treatment, including 30 in the conventional treatment group and 30 in the combined antidepressant treatment group.

Other: conventional therapy
Anti-HP, acid suppression, gastrointestinal motility regulation, etc.

No Intervention: normal control

Age, sex and education matched, right-handed 30 normal people.

Outcome Measures

Primary Outcome Measures

  1. Nepean Dyspepsia Index [Change from Baseline at 12th week]

    Evaluation of digestive tract symptoms

Secondary Outcome Measures

  1. Zung Self-Rating Anxiety Scale [Change from Baseline at 12th week]

    It is a scale measures anxiety level of patients including 20 items, and total score ranges from 20 to 80. Higher values represent a worse outcome.

  2. Zung Self-Rating Depression Scale [Change from Baseline at 12th week]

    It is a scale measures depression level of patients including 20 items, and total score ranges from 20 to 80. Higher values represent a worse outcome.

  3. The Pittsburgh Sleep Quality Index [Change from Baseline at 12th week]

    Assessment of Sleep Status

  4. quality of life survey questionnaire [Change from Baseline at 12th week]

    Assessment of quality of life

  5. Incidence of Treatment-Emergent Adverse Events [through study completion, an average of 3 years]

    Record any adverse events during treatment

  6. Functional magnetic resonance imaging [baseline and 12th week]

    assesses brain microstructures and connective white matter microstructures, and assesses functional connectivity between hemispheres

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age 18-60 years old, meeting the criteria for inclusion of refractory FD

  • HP infection negative

  • Right handedness

Exclusion Criteria:
  • Antidepressant drug allergists

  • History of gastroduodenal surgery;

  • Researchers judged suicidal ideation.

  • Women in pregnancy or lactation.

  • Patients with uncorrected narrow angle glaucoma.

  • There was a history of epileptic seizures.

  • suffering from any serious or unstable medical disease or disease.

  • Addiction to illicit drugs or alcohol and unwillingness to discontinue use during the study period.

  • Patients can't express their complaints correctly and can't cooperate with the researcher.

Contacts and Locations

Locations

Site City State Country Postal Code
1 2nd Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou Zhejiang China 310009

Sponsors and Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

Investigators

  • Principal Investigator: Yiping Chen, PHD, 2nd Affiliated Hospital, School of Medicine, Zhejiang University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Second Affiliated Hospital, School of Medicine, Zhejiang University
ClinicalTrials.gov Identifier:
NCT03973567
Other Study ID Numbers:
  • 2016-042
First Posted:
Jun 4, 2019
Last Update Posted:
Jun 4, 2019
Last Verified:
Jun 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Second Affiliated Hospital, School of Medicine, Zhejiang University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 4, 2019